Hit enter to search or ESC to close

Most Influential NEJM Papers

admin

The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society. It is among the most prestigious peer-reviewed medical journals as well as the oldest continuously published one. Paper Digest Team analyze all papers published on NEJM in the past years, and presents the 10 most influential papers for each year. This ranking list is automatically constructed based upon citations from both research papers and granted patents, and will be frequently updated to reflect the most recent changes. To find the most influential papers from other conferences, please visit Best Paper Digest page. Note: the most influential papers may or may not include the papers that won the best paper awards.

If you do not want to miss any interesting academic paper, you are welcome to sign up our free daily paper digest service to get updates on new papers published in your area every day. To search for papers with highlights, related papers, patents, grants, experts and organizations, please visit our search console. You are also welcome to follow us on Twitter and Linkedin to get updated with new conference digests.

Paper Digest Team
team@paperdigest.org

TABLE 1: Most Influential NEJM Papers

Year Rank Paper Author(s)
2020 1 First Case Of 2019 Novel Coronavirus In The United States
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: An outbreak of novel coronavirus (2019-nCoV) that began in Wuhan, China, has spread rapidly, with cases now confirmed in multiple countries. We report the first case of 2019-nCoV …		 MICHELLE L HOLSHUE et. al.
2020 2 Endometrial Cancer
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Karen H Lu; Russell R Broaddus;
2020 3 Clinical Characteristics Of Coronavirus Disease 2019 In China
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of …		 WEI-JIE GUAN et. al.
2020 4 A Novel Coronavirus From Patients With Pneumonia In China, 2019
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was …		 NA ZHU et. al.
2020 5 Aerosol and Surface Stability of SARS-CoV-2 As Compared with SARS-CoV-1
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 NEELTJE VAN DOREMALEN et. al.
2020 6 SARS-CoV-2 Viral Load In Upper Respiratory Specimens Of Infected Patients
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 LIRONG ZOU et. al.
2020 7 Transmission Of 2019-nCoV Infection From An Asymptomatic Contact In Germany
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 CAMILLA ROTHE et. al.
2020 8 Compassionate Use Of Remdesivir For Patients With Severe Covid-19
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on a compassionate-use basis …		 JONATHAN GREIN et. al.
2020 9 Suicide
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 David A Gorelick; Gopal Vyas;
2020 10 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the …		 MAXIMILIAN ACKERMANN et. al.
2019 1 Hepatocellular Carcinoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Augusto Villanueva;
2019 2 Dapagliflozin And Cardiovascular Outcomes In Type 2 Diabetes
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Baris Akinci;
2019 3 Canagliflozin And Renal Outcomes In Type 2 Diabetes And Nephropathy
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of …		 VLADO PERKOVIC et. al.
2019 4 Machine Learning In Medicine
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Alvin Rajkomar; Jeffrey Dean; Isaac Kohane;
2019 5 Machine Learning In Medicine
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Mike Fralick; Errol Colak; Muhammad Mamdani;
2019 6 Atezolizumab And Nab-Paclitaxel In Advanced Triple-Negative Breast Cancer
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Burak Y Aktas; Hakan Taban; Sercan Aksoy;
2019 7 A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
IF:6   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the …		 SABUE MULANGU et. al.
2019 8 Five-Year Survival With Combined Nivolumab And Ipilimumab In Advanced Melanoma
IF:6   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. …		 JAMES LARKIN et. al.
2019 9 Anemia Of Inflammation
IF:6   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Tomas Ganz;
2019 10 Nivolumab Plus Ipilimumab In Advanced Non-Small-Cell Lung Cancer
IF:6   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab …		 MATTHEW D HELLMANN et. al.
2018 1 Idiopathic Pulmonary Fibrosis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 David J Lederer; Fernando J Martinez;
2018 2 High-Dose Atorvastatin After Stroke Or Transient Ischemic Attack
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
2018 3 Treatment Of Periodontitis And Endothelial Function
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
2018 4 Nivolumab Plus Ipilimumab In Lung Cancer With A High Tumor Mutational Burden
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a …		 MATTHEW D HELLMANN et. al.
2018 5 Dapagliflozin And Cardiovascular Outcomes In Type 2 Diabetes
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …		 STEPHEN D WIVIOTT et. al.
2018 6 Alirocumab And Cardiovascular Outcomes After Acute Coronary Syndrome
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal …		 GREGORY G SCHWARTZ et. al.
2018 7 Thrombectomy For Stroke At 6 To 16 Hours With Selection By Perfusion Imaging
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Thrombectomy is currently recommended for eligible patients with stroke who are treated within 6 hours after the onset of symptoms. We conducted a multicenter, randomized, …		 GREGORY W ALBERS et. al.
2018 8 Cabozantinib In Patients With Advanced And Progressing Hepatocellular Carcinoma
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular …		 GHASSAN K ABOU-ALFA et. al.
2018 9 Chimeric Antigen Receptor Therapy
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Carl H June; Michel Sadelain;
2018 10 Overall Survival With Durvalumab After Chemoradiotherapy In Stage III NSCLC
IF:7   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, …		 SCOTT J ANTONIA et. al.
2017 1 Antiinflammatory Therapy With Canakinumab For Atherosclerotic Disease
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of …		 PAUL M RIDKER et. al.
2017 2 Psoriatic Arthritis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Christopher T Ritchlin; Robert A Colbert; Dafna D Gladman;
2017 3 Sickle Cell Disease
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Aubrey Milunsky;
2017 4 Health Effects Of Overweight And Obesity In 195 Countries Over 25 Years
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Although the rising pandemic of obesity has received major attention in many countries, the effects of this attention on trends and the disease burden of obesity remain uncertain. …		 ASHKAN AFSHIN et. al.
2017 5 Semaglutide And Cardiovascular Outcomes In Patients With Type 2 Diabetes
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Eli Ipp; Pauline Genter; Kristin Childress;
2017 6 Overall Survival With Combined Nivolumab And Ipilimumab In Advanced Melanoma
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients …		 JEDD D WOLCHOK et. al.
2017 7 Canagliflozin And Cardiovascular And Renal Events In Type 2 Diabetes
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Sanjay Rajagopalan; Robert Brook;
2017 8 Thrombectomy 6 To 24 Hours After Stroke With A Mismatch Between Deficit And Infarct
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The effect of endovascular thrombectomy that is performed more than 6 hours after the onset of ischemic stroke is uncertain. Patients with a clinical deficit that is …		 RAUL G NOGUEIRA et. al.
2017 9 Rivaroxaban With Or Without Aspirin In Stable Cardiovascular Disease
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. In this double-blind …		 JOHN W EIKELBOOM et. al.
2017 10 Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III Or IV Melanoma
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved …		 JEFFREY WEBER et. al.
2016 1 Polycystic Ovary Syndrome
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Giovanni Targher;
2016 2 Myasthenia Gravis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Nils E Gilhus;
2016 3 Mutations Associated With Acquired Resistance To PD-1 Blockade In Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted …		 JESSE M ZARETSKY et. al.
2016 4 Zika Virus Associated With Microcephaly
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: A widespread epidemic of Zika virus (ZIKV) infection was reported in 2015 in South and Central America and the Caribbean. A major concern associated with this infection is the …		 JERNEJ MLAKAR et. al.
2016 5 Empagliflozin And Progression Of Kidney Disease In Type 2 Diabetes
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Anil Pareek; Nitin Chandurkar; Kumar Naidu;
2016 6 Pembrolizumab Versus Chemotherapy For PD-L1-Positive Non-Small-Cell Lung Cancer
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased …		 MARTIN RECK et. al.
2016 7 A Randomized Trial Of Intensive Versus Standard Blood-Pressure Control
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Brendan B McCormick; Swapnil Hiremath; Marcel Ruzicka;
2016 8 Transcatheter Or Surgical Aortic-Valve Replacement In Intermediate-Risk Patients
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical …		 MARTIN B LEON et. al.
2016 9 Genomic Classification And Prognosis In Acute Myeloid Leukemia
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines …		 ELLI PAPAEMMANUIL et. al.
2016 10 Zika Virus And Birth Defects–Reviewing The Evidence For Causality
IF:8   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Sonja A Rasmussen; Denise J Jamieson; Margaret A Honein; Lyle R Petersen;
2015 1 PD-1 Blockade In Tumors With Mismatch-Repair Deficiency
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Yoshinari Asaoka; Hideaki Ijichi; Kazuhiko Koike;
2015 2 Pembrolizumab Versus Ipilimumab In Advanced Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune …		 CAROLINE ROBERT et. al.
2015 3 Pembrolizumab For The Treatment Of Non-small-cell Lung Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 …		 EDWARD B GARON et. al.
2015 4 Combined Nivolumab And Ipilimumab Or Monotherapy In Untreated Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 James Larkin; F Stephen Hodi; Jedd D Wolchok;
2015 5 Ezetimibe Added To Statin Therapy After Acute Coronary Syndromes
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces …		 CHRISTOPHER P CANNON et. al.
2015 6 Efficacy And Safety Of Nintedanib In Idiopathic Pulmonary Fibrosis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
2015 7 Crizotinib Versus Chemotherapy In Advanced ALK-Positive Lung Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
2015 8 Randomized Assessment Of Rapid Endovascular Treatment Of Ischemic Stroke
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% of patients die within 90 days after stroke onset or do not regain functional independence …		 MAYANK GOYAL et. al.
2015 9 Empagliflozin, Cardiovascular Outcomes, And Mortality In Type 2 Diabetes
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 …		 BERNARD ZINMAN et. al.
2015 10 Nivolumab And Ipilimumab Versus Ipilimumab In Untreated Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including …		 MICHAEL A POSTOW et. al.
2014 1 Chimeric Antigen Receptor T Cells For Sustained Remissions In Leukemia
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may …		 SHANNON L MAUDE et. al.
2014 2 Gene Editing Of CCR5 In Autologous CD4 T Cells Of Persons Infected With HIV
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: CCR5 is the major coreceptor for human immunodeficiency virus (HIV). We investigated whether site-specific modification of the gene (gene editing)–in this case, the infusion of …		 PABLO TEBAS et. al.
2014 3 AR-V7 And Resistance To Enzalutamide And Abiraterone In Prostate Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active …		 EMMANUEL S ANTONARAKIS et. al.
2014 4 Phase 3 Trials Of Solanezumab For Mild-to-moderate Alzheimer’s Disease
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Alzheimer’s disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially …		 RACHELLE S DOODY et. al.
2014 5 PD-1 Blockade With Nivolumab In Relapsed Or Refractory Hodgkin’s Lymphoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin’s lymphoma, alterations in …		 STEPHEN M ANSELL et. al.
2014 6 Genetic Basis For Clinical Response To CTLA-4 Blockade In Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against …		 ALEXANDRA SNYDER et. al.
2014 7 A Controlled Trial Of Renal Denervation For Resistant Hypertension
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Prior unblinded studies have suggested that catheter-based renal-artery denervation reduces blood pressure in patients with resistant hypertension. We designed a prospective, …		 DEEPAK L BHATT et. al.
2014 8 A Phase 3 Trial Of Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital …		 TALMADGE E KING et. al.
2014 9 Enzalutamide In Metastatic Prostate Cancer Before Chemotherapy
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after …		 TOMASZ M BEER et. al.
2014 10 Improved Overall Survival In Melanoma With Combined Dabrafenib And Trametinib
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. …		 CAROLINE ROBERT et. al.
2013 1 Safety And Tumor Responses With Lambrolizumab (anti-PD-1) In Melanoma
IF:10   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti-PD-1 antibody …		 OMID HAMID et. al.
2013 2 Chimeric Antigen Receptor-modified T Cells For Acute Lymphoid Leukemia
IF:10   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established …		 STEPHAN A GRUPP et. al.
2013 3 Nivolumab Plus Ipilimumab In Advanced Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the …		 JEDD D WOLCHOK et. al.
2013 4 Duodenal Infusion Of Donor Feces For Recurrent Clostridium Difficile
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high. We studied the effect of duodenal infusion of donor feces in …		 ELS VAN NOOD et. al.
2013 5 Targeting BTK With Ibrutinib In Relapsed Chronic Lymphocytic Leukemia
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton’s tyrosine kinase (BTK), an essential component of B-cell-receptor …		 JOHN C BYRD et. al.
2013 6 Vedolizumab As Induction And Maintenance Therapy For Crohn’s Disease
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn’s disease is unknown. In an integrated study with separate induction and maintenance trials, we assessed …		 WILLIAM J SANDBORN et. al.
2013 7 Vedolizumab As Induction And Maintenance Therapy For Ulcerative Colitis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. We conducted two integrated randomized, double-blind, …		 BRIAN G FEAGAN et. al.
2013 8 Analysis Of Circulating Tumor DNA To Monitor Metastatic Breast Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as …		 SARAH-JANE DAWSON et. al.
2013 9 Increased Survival In Pancreatic Cancer With Nab-paclitaxel Plus Gemcitabine
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We …		 DANIEL D VON HOFF et. al.
2013 10 Genomic And Epigenomic Landscapes Of Adult De Novo Acute Myeloid Leukemia
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not …		 TIMOTHY J LEY et. al.
2012 1 Safety, Activity, And Immune Correlates Of Anti-PD-1 Antibody In Cancer
IF:10   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an …		 SUZANNE L TOPALIAN et. al.
2012 2 Safety And Activity Of Anti-PD-L1 Antibody In Patients With Advanced Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host’s immune …		 JULIE R BRAHMER et. al.
2012 3 Intratumor Heterogeneity And Branched Evolution Revealed By Multiregion Sequencing
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. To examine …		 MARCO GERLINGER et. al.
2012 4 Increased Survival With Enzalutamide In Prostate Cancer After Chemotherapy
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether …		 HOWARD I SCHER et. al.
2012 5 Ulcerative Colitis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Richard N Hellman;
2012 6 Isolation Of A Novel Coronavirus From A Man With Pneumonia In Saudi Arabia
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: A previously unknown coronavirus was isolated from the sputum of a 60-year-old man who presented with acute pneumonia and subsequent renal failure with a fatal outcome in Saudi …		 Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier;
2012 7 Abiraterone In Metastatic Prostate Cancer Without Previous Chemotherapy
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We …		 CHARLES J RYAN et. al.
2012 8 Basal Insulin And Cardiovascular And Other Outcomes In Dysglycemia
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. We …		 HERTZEL C GERSTEIN et. al.
2012 9 Immune-correlates Analysis Of An HIV-1 Vaccine Efficacy Trial
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify …		 BARTON F HAYNES et. al.
2012 10 Placebo-controlled Phase 3 Study Of Oral BG-12 For Relapsing Multiple Sclerosis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity …		 RALF GOLD et. al.
2011 1 Chimeric Antigen Receptor-modified T Cells In Chronic Lymphoid Leukemia
IF:10   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells …		 David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June;
2011 2 Improved Survival With Vemurafenib In Melanoma With BRAF V600E Mutation
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF …		 PAUL B CHAPMAN et. al.
2011 3 Niacin In Patients With Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with …		 WILLIAM E BODEN et. al.
2011 4 Adenovirus-associated Virus Vector-mediated Gene Transfer In Hemophilia B
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Hemophilia B, an X-linked disorder, is ideally suited for gene therapy. We investigated the use of a new gene therapy in patients with the disorder. We infused a single dose of a …		 AMIT C NATHWANI et. al.
2011 5 Abiraterone And Increased Survival In Metastatic Prostate Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Alfredo Berruti; Anna Pia; Massimo Terzolo;
2011 6 Fidaxomicin Versus Vancomycin For Clostridium Difficile Infection
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients generally have a response to oral vancomycin or …		 THOMAS J LOUIE et. al.
2011 7 Ipilimumab Plus Dacarbazine For Previously Untreated Metastatic Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with …		 CAROLINE ROBERT et. al.
2011 8 FOLFIRINOX Versus Gemcitabine For Metastatic Pancreatic Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Vanja Vaccaro; Isabella Sperduti; Michele Milella;
2011 9 A Prospective Natural-history Study Of Coronary Atherosclerosis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Atherosclerotic plaques that lead to acute coronary syndromes often occur at sites of angiographically mild coronary-artery stenosis. Lesion-related risk factors for such events …		 GREGG W STONE et. al.
2011 10 The Pathogenesis Of Rheumatoid Arthritis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Iain B McInnes; Georg Schett;
2010 1 Improved Survival With Ipilimumab In Patients With Metastatic Melanoma
IF:10   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab–which blocks cytotoxic …		 F STEPHEN HODI et. al.
2010 2 Effects Of Combination Lipid Therapy In Type 2 Diabetes Mellitus
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with …		 HENRY N GINSBERG et. al.
2010 3 Sipuleucel-T Immunotherapy For Castration-resistant Prostate Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
 Chadi Nabhan;
2010 4 Inhibition Of Mutated, Activated BRAF In Metastatic Melanoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test …		 KEITH T FLAHERTY et. al.
2010 5 Anaplastic Lymphoma Kinase Inhibition In Non-small-cell Lung Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We …		 EUNICE L KWAK et. al.
2010 6 Anti-GD2 Antibody With GM-CSF, Interleukin-2, And Isotretinoin For Neuroblastoma
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and …		 ALICE L YU et. al.
2010 7 Pioglitazone, Vitamin E, Or Placebo For Nonalcoholic Steatohepatitis
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease. We randomly assigned 247 …		 ARUN J SANYAL et. al.
2010 8 Triple-negative Breast Cancer
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast …		 William D Foulkes; Ian E Smith; Jorge S Reis-Filho;
2010 9 Brentuximab Vedotin (SGN-35) For Relapsed CD30-positive Lymphomas
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: Hodgkin’s lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies …		 ANAS YOUNES et. al.
2010 10 EML4-ALK Mutations In Lung Cancer That Confer Resistance To ALK Inhibitors
IF:9   Related Papers   Related Patents   Related Grants   Related Orgs   Related Experts   Details
Abstract: The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non-small-cell lung …		 YOUNG LIM CHOI et. al.